XML 16 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Statements of Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Net loss $ (9,793,324) $ (12,047,796)
Available for sale securities - net unrealized loss 0 (486)
Total other comprehensive loss 0 (486)
Comprehensive loss (9,793,324) (12,048,282)
Comprehensive loss attributable to noncontrolling interests (433,497) (66,879)
Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders $ (9,359,827) $ (11,981,403)